Archives

New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

ALung’s artificial lung technology selected for use in landmark respiratory failure trial

2 December 2015 Press Release

The Hemolung Respiratory Assist System will be exclusively utilized in the 1120-patient study. PITTSBURGH  (December 2, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today its participation in the world’s first and largest pivotal trial of ECCO2R technology. The (read more)

Extracorporeal carbon dioxide removal with the Hemolung RAS to avoid intubation and invasive mechanical ventilation in an acute exacerbation of chronic obstructive pulmonary disease: A case report

16 January 2014 Recent News, User Reports

Hergen Buscher, MD Sydney, Australia This case report describes the use of extracorporeal carbon dioxide removal (ECCO2R) to successfully avoid intubation and mechanical ventilation in an 59-year old man who was experiencing an acute exacerbation of chronic obstructive pulmonary disease (COPD). Invasive mechanical ventilation was considered undesirable due to the potential prognosis of long-term ventilator (read more)